5 May, 2025

Luminary was highlighted in Cell & Gene Therapy Review.

You can read the full article here.

23 APR, 2025

Jeff Liter, Chief Executive Officer and Founder of Luminary Therapeutics, joined NPR’s BioTech Nation to discuss Luminary’s allogeneic manufacturing platform and ongoing clinical trials.

You can listen to the discussion between Jeff and BioTech Nation’s host, Dr. Moira Gunn here.

10 DEC, 2024

Jeff Liter, Chief Executive Officer and Founder of Luminary Therapeutics, discusses multiple myeloma on Episode 7 of Patient Innovations Podcast.

You can listen to the podcast episode here or find it in your podcast player by looking for Episode 7 of Patient Innovations Podcast.

10 MAY, 2023

Jeff Liter, Chief Executive Officer and Founder of Luminary Therapeutics, discusses Luminary’s unique allogeneic platform and two approved INDs on Oncology Tube

Jeff Liter was on Oncology Tube to discuss Luminary’s novel allogeneic manufacturing platform, two approved INDs, and their solid tumor program. See the full video here.

24 APR, 2023

Jeff Liter, Chief Executive Officer and Founder of Luminary Therapeutics, was on the Empowered Patient Podcast

Jeff Liter was on the Empowered Patient Podcast to discuss Luminary’s novel allogeneic manufacturing platform for treating multiple types of solid tumors.

13 APR, 2023

Jeff Liter, Chief Executive Officer and Founder of Luminary Therapeutics, presented at the 2023 Cell & Gene Meeting on the Med in Barcelona, Spain

Jeff Liter presented on Luminary’s unique allogeneic manufacturing platform. Watch the presentation here.

21 DEC, 2022

The MIF invests in Luminary Therapeutics

The Myeloma Investment Fund (MIF), which is a venture philanthropy subsidiary of the Multiple Myeloma Research Foundation (MMRF), announced today that they are investing in Luminary Therapeutics. Read the full press release here.

26 JUL, 2022

Beau Webber, Chief Science Officer and Founder of Luminary Therapeutics, to present at 3rd Gamma Delta T Therapies Summit in Boston, MA.

The presentation from Beau Webber, PhD, will take place at 3:00 PM EST, where Beau will talk about Luminary Therapeutics’ novel Gamma Delta manufacturing platform.

19 JUL, 2022

Luminary Therapeutics selected as a 2022 showcase company in NIH/NCI’s investor initiative program.

The National Cancer Institute’s (NCI) Small Business Innovation Research Development Center selected Luminary Therapeutics to participate in its 2022–2023 Investor Initiatives program. Read full press release here.

29 JUN, 2022

Branden Moriarity, Chief Innovation Officer of Luminary Therapeutics, to present at Onco Cell Therapy Summit in Boston, MA.

The presentation from Branden Moriarity, PhD, at OCTS USA 2022 will take place at 2:00 PM EST.

21 APR, 2022

Jeff Liter, Chief Executive Officer and Founder of Luminary Therapeutics, to present at the Cell & Gene Meeting on the Mediterranean in Barcelona, Spain

Jeff will discuss the benefits of a CAR design with three distinct antigens to avoid antigen escape at the Cell & Gene Meeting on the Mediterranean.

17 MAR, 2022

FDA clears Luminary’s BAFF CAR-T therapy for a Phase I trial

This Phase I trial will be a basket study in Non-Hodgkin Lymphoma centered around Mantle Cell Cancers.  The trial is expected to start recruiting patients at the Cleveland Clinic in Aug/Sep of 2022.

12 OCT, 2021

Beau Webber, PhD, Chief Science Officer and Founder of Luminary Therapeutics, to present at the Cell & Gene Meeting on the Mesa in Carlsbad, CA

Luminary Therapeutics’ Chief Science Officer and founder, Beau Webber, PhD to present at the 2021 Cell & Gene Meeting on the Mesa, October 12, 2021 at 1:15 PM PST.

28 SEP, 2021

Jeff Liter, CEO & Founder of Luminary Therapeutics, to present at live session: Advantages of Non-Viral Delivery for Cell Therapy Manufacturing

Luminary Therapeutics’ CEO and founder, Jeff Liter to present at the third edition of Phacilitate’s Virtual Member-only series, 2021 Advanced Therapies Connect, September 28, 2021. Session will be moderated by Nithya Jesuraj, Product Manager, Cell and Gene Therapy at Bio-Techne.

23 FEB, 2021

Bio-Techne And Luminary Therapeutics Sign License Agreement For Use Of Bio-Techne’s TcBuster™ For The Development Of Luminary’s CAR-T Cell Therapies

Bio-Techne Corporate (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster^™ for the manufacturing of gene-modified cell therapies. TcBuster^™ is Bio-Techne’s proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing.  Read full press release.

o7 JUL, 2020

Luminary Therapeutics and Case Western Reserve University Enter Collaboration

Luminary Therapeutics and Case Western Reserve University enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome. Read full press release.

21 JAN, 2020

Phacilitate Leaders World & World Stem Cell Summit 2020

Luminary’s VP of Corporate Development will be attending Phacilitate Leaders World & World Stem Cell Summit 2020 in Miami, Jan 21-24, 2020

12 NOV, 2019

Luminary files patent for Universal Receptor for Immunotherapy

Jeff Liter CEO of Luminary notes this universal receptor has the ability to disrupt targeting multiple cancer antigens invivo.

04 MAR, 2019

Luminary Tx teams with 20 year licensing pharma veteran to seek novel CAR’s and TCR’s IP

Luminary is in negotiations with three key cancer centers for exclusive licenses of next generation CAR’s and TCR’s.

30 FEB, 2019

Dr. Arek Dudek MD teams up with Luminary in order to accelerate new Immunotherapies

Dr Dudek, hails from the Medical University of Warsaw, Poland; internal medicine residency, Pinnacle Health Hospitals, Harrisburg, PA; fellowship in hematology and oncology, and the University of Minnesota.

26 FEB, 2019

Luminary is initiating partnerships with key antibody companies

Luminary is initiating partnerships with key antibody companies to discover new Chimeric Antigen Receptors (CAR’s). Expect new announcements in the Spring of 2020.

20 FEB, 2019

Luminary will be submitting three SBIR grants on Jan 6 2020

David Largaespada notes that these grants if awarded will accelerate key research at Luminary for our prostate and pancreatic cancer initiatives.